NovaBridge Biosciences (NBP) Operating Margin (2019 - 2023)

NovaBridge Biosciences (NBP) posted quarterly Operating Margin of 789260.0% for Q4 2023, down 23279.43% on a QoQ basis from 3375.87% in Q3 2023.

NovaBridge Biosciences (NBP) Operating Margin (2019 - 2023) Analysis & Trends

NovaBridge Biosciences (NBP) has reported Operating Margin for 2 consecutive years, with 789260.0% the latest figure, recorded in Q4 2023.

Quarterly Operating Margin changed N/A year-over-year to 789260.0% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 4469691.91% (changed N/A YoY) and the FY2023 annual result came in at 11395.09%, down 797292.0% from the prior year.
Operating Margin eased to 789260.0% in Q4 2023 per NBP's latest filing, from 3375.87% in the prior quarter.
Over the last five years, Operating Margin for NBP reached as high as 2042.94% in Q3 2019 and fell as low as 789260.0% in Q4 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Operating Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	NovaBridge Biosciences	389.86 Mn	389.86 Mn	-	-

Download Data